ArticleTropical medicine and health2022
Post-chikungunya arthritis: a longitudinal study in a tertiary care hospital in Bangladesh.
Article in Tropical medicine and health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Arthritis models for studying chikungunya virus joint inflammation.Communications biology · 2026Review
- Climate Change-Mediated Temperature Extremes: Effects on the Immune System and Associations with Immune-Related Diseases.Clinical reviews in allergy & immunology · 2026Review
- Chronic phase of Chikungunya: understanding the impact of joint pain using data science and artificial intelligence.Tropical medicine and health · 2026Article
- Identification of a TCR signature in peripheral blood derived CD4+ T cells, associated with chronic chikungunya disease, suggests a conducive, female-biased, background immune profile.Frontiers in immunology · 2026Article
- Predictors of chronic arthralgia following chikungunya virus infection.GMS hygiene and infection control · 2026Article
- Article
- The role of autoantibodies in post-chikungunya viral arthritis disease severity.Microbiology spectrum · 2025Article
- Chikungunya Fever and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2025Review
- The climate emergency for rheumatologists: where do we stand?Clinical rheumatology · 2025Review
- Chikungunya Virus: Unveiling Its Global Impact (2002-2024).Interdisciplinary perspectives on infectious diseases · 2025Review
- Central nervous system infections in the tropics.Current opinion in infectious diseases · 2024Review
- The Chikungunya anxiety scale (CHIKAS): Development, validation, and relationship between its items and illness-related factors.Industrial psychiatry journal · 2023Article
- Asymptomatic arbovirus and campylobacter infections in German travelers to Asia.Archives of virology · 2023Article
- Review
- Role of cytokines, chemokines, C3a, and mannose-binding lectin in the evolution of the chikungunya infection.American journal of clinical and experimental immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveTo identify the clinical patterns and consequences of post-chikungunya arthritis was the study's objective.
methodsThis longitudinal study was carried out among 143 Chikungunya virus (CHIKV) infected adult patients at the rheumatology department, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, during the outbreak of CHIKV infection in 2017. The disease was categorized into three phases: acute or febrile (lasting up to 10 days), subacute (11-90 days), and chronic (> 90 days). Patients who progressed towards the chronic phase were followed up to 1-year. Post-CHIKV de novo chronic inflammatory rheumatisms (CIRs) were characterized by persistent mono or oligoarthritis, undifferentiated polyarthritis, or meet the criteria rheumatoid arthritis (RA) or Spondyloarthritis (SpA). In addition, functional status was assessed by the validated Bangla version of the Health Assessment Questionnaire (HAQ).
resultsMean age was 43.3 ± 11.5 years, and 51.0% were male. Within 1-year follow-up, 60 (41.9%) patients were suffering from arthralgia/ arthritis. Of them 52 patients did not have any pre-existing arthralgia/arthritis. 35 (65.3%) had undifferentiated arthritis, 10 (19.2%) had SpA, and 7 (13.5%) had RA. Patients with pre-existing rheumatological disorders, 6(4.2%) had SpA, 1(0.7%) had RA and 1(0.7%) had osteoarthritis. Polyarthralgia (n = 33, 55.0%) and polyarthritis (n = 20, 33.3%) were the main presentations. Female gender (OR: 0.45; CI: 0.21-0.96), positive IgG (OR: 0.30; CI: 0.12-0.76), and moderate to severe functional disability (OR: 3.46; CI: 1.62-7.40) were independent predictors of developing chronic post-CHIKV rheumatism.
conclusionsAt 1-year follow-up, more than one-third of the patients remained symptomatic. Female gender, positive IgG, and moderate to severe functional disability contributed to the development of chronicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.